Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare non-Hodgkin lymphoma that arises in and is confined to the lung at the time of diagnosis. Representative examples include bronchial mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma.
Biomarker and diagnostic research for lung non-Hodgkin lymphoma has been reported in the published literature.
No clinical trials have been registered for lung non-Hodgkin lymphoma.
109 publications have been identified in PubMed for lung non-Hodgkin lymphoma. Research spans Epidemiology / Natural History (34%), Case Report / Case Series (31%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 37 | 34% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 3:07 PM UTC
Patient case studies
34 |
31% |
Clinical study results | 13 | 12% |
Research summaries | 11 | 10% |
Laboratory research | 9 | 8% |
Testing and diagnosis research | 3 | 3% |
Other research | 1 | 1% |
New treatment approaches | 1 | 1% |
Tariq MA (2026). [PMID: 42109955](https://pubmed.ncbi.nlm.nih.gov/42109955/). *Cureus*. [Case Report / Case Series]
Cabanillas F (2026). [PMID: 41077504](https://pubmed.ncbi.nlm.nih.gov/41077504/). *Clinical lymphoma, myeloma & leukemia*. [Review / Meta-Analysis]
Han WM (2026). [PMID: 41567716](https://pubmed.ncbi.nlm.nih.gov/41567716/). *EClinicalMedicine*. [Epidemiology / Natural History]
Ahmed N (2026). [PMID: 42123761](https://pubmed.ncbi.nlm.nih.gov/42123761/). *Molecules*. [Basic Science / Preclinical]
Zhang B (2026). [PMID: 41970458](https://pubmed.ncbi.nlm.nih.gov/41970458/). *Lancet Reg Health West Pac*. [Epidemiology / Natural History]
Rashid A (2026). [PMID: 41539015](https://pubmed.ncbi.nlm.nih.gov/41539015/). *Clinical oncology (Royal College of Radiologists (Great Britain))*. [Epidemiology / Natural History]
Palomba ML (2026). [PMID: 41692020](https://pubmed.ncbi.nlm.nih.gov/41692020/). *Lancet (London, England)*. [Clinical Trial Publication]
Wei X (2026). [PMID: 42174190](https://pubmed.ncbi.nlm.nih.gov/42174190/). *Cancer Gene Ther*. [Basic Science / Preclinical]
Liu H (2026). [PMID: 41491512](https://pubmed.ncbi.nlm.nih.gov/41491512/). *[Zhonghua yan ke za zhi] Chinese journal of ophthalmology*. [Basic Science / Preclinical]
Loap P (2026). [PMID: 42241771](https://pubmed.ncbi.nlm.nih.gov/42241771/). *Cancer Radiother*. [Review / Meta-Analysis]
AI-curated news mentioning lung non-Hodgkin lymphoma
Updated Sep 5, 2026
A case report highlights a rare instance of dural follicular non-Hodgkin lymphoma presenting as a chronic subdural hematoma. This finding contributes to the understanding of atypical presentations of lymphomas and may aid in differential diagnosis.
Legend Biotech's in vivo CAR T therapy shows promising results with all six non-Hodgkin lymphoma patients responding to treatment. This success positions the company as a potential acquisition target, according to analysts at Oppenheimer.
Recent research highlights new investigational agents targeting cutaneous T-cell lymphoma within the broader category of non-Hodgkin lymphoma. These developments may offer novel therapeutic options for patients suffering from this rare condition.
A rare case of Cladosporium cladosporioides fungemia in a patient with non-Hodgkin lymphoma has been documented, highlighting the complexities of fungal infections in immunocompromised individuals. This case contributes to the understanding of rare fungal pathogens in the context of hematological malignancies.
ModeX Therapeutics is advancing MDX2003, a tetraspecific therapy for non-Hodgkin lymphoma, aiming for improved efficacy and safety. The therapy is currently in phase 1 trials and is designed for community clinic use through intravenous administration.